H Lee Moffitt Cancer Center and Research Institute H. Lee Moffitt Cancer Center
Welcome,         Profile    Billing    Logout  
 7 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Han, Hyo
NATASHA, NCT05325632: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Recruiting
2
53
US
HER-2 pulsed DC1, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Paclitaxel, Abraxane, Resection surgery
H. Lee Moffitt Cancer Center and Research Institute, ImmunoRestoration
HER2-positive Breast Cancer
10/25
10/26
MCC-18936, NCT03112590: Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Completed
1/2
51
US
Interferon-gamma (IFN-γ), Actimmune®, signaling proteins, Paclitaxel, Abraxane®, Trastuzumab, Herceptin®, Pertuzumab, PERJETA®, monoclonal antibody, Post Therapy Surgery
H. Lee Moffitt Cancer Center and Research Institute, Horizon Pharma Ireland, Ltd., Dublin Ireland
Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
03/21
02/23
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
Dunning, Beverly
No trials found
Carlton, Brooke
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Han, Hyo
NATASHA, NCT05325632: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Recruiting
2
53
US
HER-2 pulsed DC1, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Paclitaxel, Abraxane, Resection surgery
H. Lee Moffitt Cancer Center and Research Institute, ImmunoRestoration
HER2-positive Breast Cancer
10/25
10/26
MCC-18936, NCT03112590: Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Completed
1/2
51
US
Interferon-gamma (IFN-γ), Actimmune®, signaling proteins, Paclitaxel, Abraxane®, Trastuzumab, Herceptin®, Pertuzumab, PERJETA®, monoclonal antibody, Post Therapy Surgery
H. Lee Moffitt Cancer Center and Research Institute, Horizon Pharma Ireland, Ltd., Dublin Ireland
Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
03/21
02/23
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
Dunning, Beverly
No trials found
Carlton, Brooke
No trials found

Download Options